In particular, taking into account the role of AKT in cisplatin resistance in different cancers as well as the observed sensitization of cisplatin-sensitive and -resistant ovarian cancer cells by adding capivasertib, combining AKT inhibitors with cisplatin as the hub of the systemic therapy for metastasized PeCa presents an intriguing novel therapeutic option [34,35,43]. The gene discussed is AKT1; the disease is ovarian cancer.